参考文献/References:
[1] 中华中医药学会.骨质疏松性骨折中医诊疗指南[J].中医正骨,2023,35(1):1-9.
[2] 中国疾病预防控制中心慢性非传染性疾病预防控制中心,中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查报告 2018[M].北京:人民卫生出版社,2021:21-22.
[3] QASEEM A,HICKS L A,ETXEANDIA-IKOBALTZETA I,et al.Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults:a living clinical guideline from the American College of Physicians[J].Ann Intern Med,2023,176(2):224-238.
[4] 中国营养学会.中国居民膳食营养素参考摄入量(2023版)[M].北京:人民卫生出版社,2023:194-205.
[5] SUBARAJAN P,ARCEO-MENDOZA R M,CAMACHO P M.Postmenopausal osteoporosis:a review of latest guidelines[J].Endocrinol Metab Clin North Am,2024,53(4):497-512.
[6] LEBOFF M S,GREENSPAN S L,INSOGNA K L,et al.The clinician's guide to prevention and treatment of osteoporosis[J].Osteoporos Int,2022,33(10):2049-2102.
[7] REIS A R,SANTOS R K F,DOS SANTOS C B,et al.Supplementation of vitamin D isolated or calcium-associated with bone remodeling and fracture risk in postmenopausal women without osteoporosis:a systematic review of rando-mized clinical trials[J].Nutrition,2023,116:112151.
[8] CIANCIOLO G,CAPPUCCILLI M,TONDOLO F,et al.Vitamin D effects on bone homeostasis and cardiovascular system in patients with chronic kidney disease and renal transplant recipients[J].Nutrients,2021,13(5):1453.
[9] PLUDOWSKI P.Supplementing vitamin D in different patient groups to reduce deficiency[J].Nutrients,2023,15(17):3725.
[10] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2022)[J].中国全科医学,2023,26(14):1671-1691.
[11] YU C H,TSENG H K,CHIEN D K,et al.Over-supplement of vitamin D may cause delirium,abdominal distension,and muscle weakness in the elderly:a case report and literature review[J].Medicine(Baltimore),2024,103(52):e41057.
[12] AYERS C,KANSAGARA D,LAZUR B,et al.Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis:a living systematic review and network meta-analysis for the American College of Physicians[J].Ann Intern Med,2023,176(2):182-195.
[13] KEHOE T,BLIND E,JANSSEN H.Regulatory aspects of the development of drugs for metabolic bone diseases-FDA and EMA perspective[J].Br J Clin Pharmacol,2019,85(6):1208-1212.
[14] BEAUDOIN C,MOORE L,GAGN? M,et al.Performance of predictive tools to identify individuals at risk of non-traumatic fracture:a systematic review,meta-analysis,and meta-regression[J].Osteoporos Int,2019,30(4):721-740.
[15] THOMASIUS F,KURTH A,BAUM E,et al.Clinical practice guideline:the diagnosis and treatment of osteoporosis[J].Dtsch Arztebl Int,2025,122(1):12-18.
[16] KUMAR S,WANG M,KIM A S,et al.Denosumab discontinuation in the clinic:implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures [J/OL].J Bone Miner Res,2025[2025-02-10].https://pubmed.ncbi.nlm.nih.gov/40057981.
[17] GU X,ZHANG L,CHEN X,et al.Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6,TNF-α,and IGF-1 in patients with osteoporosis[J].Int J Clin Pharmacol Ther,2025,63(4):154-159.
[18] BILEZIKIAN J P,LIN C J F,BROWN J P,et al.Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus:analyses from the FREEDOM extension cross-over group[J].Osteoporos Int,2019,30(9):1855-1864.
[19] LAMY O,EVERTS-GRABER J,RODRIGUEZ E G.Denosumab for osteoporosis treatment:when,how,for whom,and for how long.A pragmatical approach[J].Aging Clin Exp Res,2025,37(1):70.
[20] DAVIS S,SIMPSON E,HAMILTON J,et al.Denosumab,raloxifene,romosozumab and teriparatide to prevent osteoporotic fragility fractures:a systematic review and economic evaluation[J].Health Technol Assess,2020,24(29):1-314.
[21] GREGSON C L,ARMSTRONG D J,BOWDEN J,et al.UK clinical guideline for the prevention and treatment of osteoporosis[J].Arch Osteoporos,2022,17(1):58.
[22] KANIS J A,JOHANSSON H,HARVEY N C,et al.An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines:a report for the National Osteoporosis Guideline Group(NOGG)[J].Osteoporos Int,2021,32(10):1951-1960.
[23] TETSUNAGA T,TETSUNAGA T,NISHIDA K,et al.Denosumab and alendronate treatment in patients with back pain due to fresh osteoporotic vertebral fractures [J].J Orthop Sci,2017,22(2):230-236.
[24] DIKER-COHEN T,ROSENBERG D,AVNI T,et al.Risk for infections during treatment with denosumab for osteoporosis:a systematic review and meta-analysis[J].J Clin Endocrinol Metab,2020,105(5):dgz322.
[25] LIM S Y,BOLSTER M B.Clinical utility of romosozumab in the management of osteoporosis:focus on patient selection and perspectives[J].Int J Womens Health,2022,14:1733-1747.
[26] SAAG K G,PETERSEN J,BRANDI M L,et al.Romosozumab or alendronate for fracture preventionin women with osteoporosis[J].N Engl J Med,2017,377(15):1417-1427.
[27] KERSCHAN-SCHINDL K.Romosozumab:a novel bone anabolic treatment option for osteoporosis?[J].Wien Med Wochenschr,2020,170(5-6):124-131.
[28] WILLEMS D,JAVAID M K,PINEDO-VILLANUEVA R,et al.Importance of time point-specific indirect treatment comparisons of osteoporosis treatments:a systematic literature review and network meta-analyses[J].Clin Ther,2022,44(1):81-97.
[29] LEE D O,HONG Y H,CHO M K,et al.The 2024 guidelines for osteoporosis-korean society of menopause:part[J].J Menopausal Med,2024,30(2):55-77.
[30] NISHIKAWA A,ISHIDA T,TAKETSUNA M,et al.Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan:final report[J].Clin Interv Aging,2016,11:913-925.
[31] MUNEKAWA C,HASHIMOTO Y,KITAGAWA N,et al.Effect of teriparatide on bone mineral density and trabecular bone score in type 2 diabetic patients with osteoporosis:a retrospective cohort study[J].Medicina(Kaunas),2022,58(4):481.
[32] GUYER L,LEHMANN O,WENGER M,et al.Long-term impact of teriparatide on bone mineral density,trabecular bone score,and fracture risk relative to total hip T-score:a two-decade,registry-based cohort study[J/OL].Bone,2025[2025-02-10]. https://pubmed.ncbi.nlm.nih.gov/40054513.
[33] VETRANO D,AGUANNO F,PASSASEO A,et al.Efficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover:a real-world experience[J/OL].Int Urol Nephrol,2025[2025-02-10].https://pubmed.ncbi.nlm.nih.gov/39871033.
[34] KREGE J H,GILSENAN A W,KOMACKO J L,et al.Teriparatide and osteosarcoma risk:history,science,elimination of boxed warning,and other label updates[J].JBMR Plus,2022,6(9):e10665.
[35] ROSSINI M,ADAMI G,ADAMI S,et al.Safety issues and adverse reactions with osteoporosis management[J].Expert Opin Drug Saf,2016,15(3):321-332.
[36] U.S.Preventive Services Task Force.Hormone therapy for the prevention of chronic conditions in postmenopausal women:recommendations from the U.S.[J].Ann Intern Med,2005,142(10):855-860.
[37] HSU S H,CHEN L R,CHEN K H.Primary osteoporosis induced by androgen and estrogen deficiency:the molecular and cellular perspective on pathophysiological mechanisms and treatments[J].Int J Mol Sci,2024,25(22):12139.
[38] ABDELAZIM I A,ABDELRAZAK K M,AL-KADI M,et al.Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis[J].Arch Osteoporos,2014,9:189.
[39] LIU H,YAN W,LUO D,et al.A real world pharmacovigilance study of raloxifene based on the FDA adverse event reporting system(FAERS)[J/OL].Expert Opin Drug Saf,2024:1-9[2025-02-10].https://pubmed.ncbi.nlm.nih.gov/39690869.
中医正骨2025年5月第37卷第5期 J Trad Chin Orthop Trauma,2025,Vol.37,No.5(总325)
(总326)中医正骨2025年5月第37卷第5期 J Trad Chin Orthop Trauma,2025,Vol.37,No.5
[40] MOTLANI G,MOTLANI V,ACHARYA N,et al.Novel advances in the role of selective estrogen receptor modulators in hormonal replacement therapy:a paradigm shift[J].Cureus,2023,15(11):e49079.
[41] ROUX C,THOMAS T,PACCOU J,et al.Refracture and mortality following hospitalization for severe osteoporotic fractures:the fractos study[J].JBMR Plus,2021,5(7):e10507.
[42] PETERSEN T G,RUBIN K H,JAVAID M K,et al.Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE[J/OL].Osteoporos Int,2025[2025-02-10].https://pubmed.ncbi.nlm.nih.gov/39992408.DOI:10.1007/s00198-025-07436-x.
[43] FUGGLE N,LASLOP A,RIZZOLI R,et al.Treatment of osteoporosis and osteoarthritis in the oldest old[J].Drugs,2025,85(3):343-360.
[44] SNG G G R,REGINSTER J Y,ALOKAIL M S,et al.Osteoporosis in men-east and west:can the twain meet?A perspective from Asia[J].Osteoporos Sarcopenia,2024,10(4):131-144.
相似文献/References:
[1]许兵,叶小雨,王萧枫,等.小管径经皮椎体后凸成形术治疗
骨质疏松性椎体重度压缩骨折[J].中医正骨,2015,27(11):29.
[2]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的
胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[3]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(05):7.
[4]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(05):12.
[5]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统
在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[6]谢小利,李晓程.经皮椎体后凸成形术治疗骨质疏松性椎体
压缩骨折的围手术期护理[J].中医正骨,2015,27(05):79.
[7]郭世明,石玲玲,郭志民,等.手法复位石膏外固定和切开复位钢板内固定治疗
骨质疏松性桡骨远端骨折的比较研究[J].中医正骨,2015,27(04):15.
GUO Shiming,SHI Lingling,GUO Zhimin,et al.A comparative study of manual reduction and plaster external fixation versus open reduction and plate internal fixation for treatment of osteoporotic distal radius fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(05):15.
[8]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(05):27.
[9]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证
患者骨密度的影响[J].中医正骨,2013,25(11):19.
Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(05):19.
[10]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(05):20.
[11]杨庆贤,曹翠萍,曹哲.常规抗骨质疏松疗法联合腰腹肌训练治疗原发性骨质疏松腰背部疼痛[J].中医正骨,2017,29(06):72.
[12]梁博程,史晓林,施振宇,等.强骨膏方对绝经后骨质疏松性椎体骨折患者经皮椎体后凸成形术后骨代谢及生活质量的影响[J].中医正骨,2020,32(05):6.
LIANG Bocheng,SHI Xiaolin,SHI Zhenyu,et al.Influence of Qianggu(强骨)paste on bone metabolism and life quality of patients who received percutaneous kyphoplasty for postmenopausal osteoporotic vertebral fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2020,32(05):6.